Hepatitis C virus-cell interactions and their role in pathogenesis

Clinics in Liver Disease

Volumn 7, Issue 1, 2003, Pages 67-88

  Polyak, Stephen J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYTOKINE; INTERLEUKIN 8; REBETRON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS PROTEIN;

CHRONIC HEPATITIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST CELL; HUMAN; LIFE CYCLE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS CORE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; CELL COMMUNICATION; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 0037299112     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00075-2     Document Type: Review

References (149)

1. Di Bisceglie AM. Liver transplantation for hepatitis C: the promise and the challenge. Hepatology 1995;22:660-2.
2. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992;16:865-76.
3. Bellentani S, Miglioli L, Masutti F, Saccoccio G, Tiribelli C. Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microbes and Infection 2000;2:1757-63.
4. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
5. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
6. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-406.
7. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region I as a decoy. J Virol 1999;73:2938-46.
8. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C infection are associated with different vigor of the antiviral cell-mediated immune response. J Clin Invest 1996;98:706-14.
9. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JYN. Intrahepatic hepatitis C virus-specific cytotoxic T-lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998;28:225-30.
10. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-49.
11. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-95.
12. Oldach D, Gale M, Almiroudis D, Ray S, Thomas D, Thimme R, et al. Evolving HCV-NS5A sequence and protein kinase (PKR)-NS5A interaction phenotypes in acute HCV infection. Presented at the 8th International Symposium on Hepatitis C Virus and Related Viruses. Paris, Sept 2-5, 2001.
13. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26:71S-7S.
14. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
15. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-32.
17. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
18. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alfa-2a compared with interferon alfa-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
19. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32:647-53.
20. Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, et al. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res 1999;59:3980-4.
21. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
22. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
23. Dubuisson J. Folding, assembly, and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 2000;242:135-48.
24. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992;181:293-300.
25. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (Berl) 1993; 182:329-34.
26. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999;96:12766-71.
27. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41.
28. Allander T, Forns X, Emerson SU, Purcell RH, Bukh J. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. Virology 2000;277:358-67.
29. Meola A, Sbardellati A, Ercole BB, Cerretani M, Pezzanera M, Ceccacci A, et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 2000;74:5933-8.
30. Zhao X, Tang ZY, Klumpp B, Wolff-Vorbeck G, Barth H, Levy S, et al. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest 2002;109:221-32.
31. Wellnitz S, Klumpp B, Barth H, Ito S, Depla E, Dubuisson J, et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 2002;76:1181-93.
32. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15.
33. Spear PG, Eisenberg RJ, Cohen GH. Three classes of cell surface receptors for alfaherpesvirus entry. Virology 2000;275:1-8.
34. Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 2001;108:503-10.
35. Meyer K, Basu A, Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 2000;276:214-26.
36. Young KC, Chang TT, Liou TC, Wu HL. Detection of hepatitis C virus RNA in peripheral blood mononuclear cells and in saliva. J Med Virol 1993;41:55-60.
37. Willems M, Peerlinck K, Moshage H, Deleu I, Van DEC, Vermylen J, et al. Hepatitis C virus RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol 1994;42:272-8.
38. Wang JT, Sheu JC, Lin JT, Wang TH, Chen DS. Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. J Infect Dis 1992;166:1167-9.
39. Qian C, Camps J, Maluenda MD, Civeira MP, Prieto J. Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alfa-interferon therapy. J Hepatol 1992; 16:380-3.
40. Bartolome J, Castillo I, Quiroga JA, Navas S, Carreno V. Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells. J Hepatol 1993;17(Suppl 3):590-3.
41. Bouffard P, Hayashi PH, Acevedo R, Levy N, Zeldis JB. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992;166:1276-80.
42. Ferri C, Monti M, La CL, Longombardo G, Greco F, Pasero G, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993;82:3701-4.
43. Gabrielli A, Manzin A, Candela M, Caniglia ML, Paolucci S, Danieli MG, et al. Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. Clin Exp Immunol 1994;97:87-93.
44. Bronowicki JP, Loriot MA, Thiers V, Grignon Y, Zignego AL, Brechot C. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology 1998; 28:211-8.
45. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis 1998;178:1189-92.
46. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-9.
47. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195:35-41.
48. Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 2001;31:166-75.
49. Jin M, Park J, Lee S, Park B, Shin J, Song KJ, et al. Hantaan virus enters cells by clathrin-dependent receptor-mediated endocytosis. Virology 2002;294:60-9.
50. Bishop NE. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 1998;41:261-71.
51. Borrow P, Oldstone MB. Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology 1994;198:1-9.
52. Helenius A, Marsh M, White J. Inhibition of Semliki forest virus penetration by lysosomotropic weak bases. J Gen Virol 1982;58(Pt 1):47-61.
53. Polyak SJ, Rawls WE, Hamish DG. Characterization of Pichinde virus infection of cells of the monocytic lineage. J Virol 1991;65:3575-82.
54. Randolph VB, Stollar V. Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures. J Gen Virol 1990;71:1845-50.
55. Walewski JL, Keller TR, Stump DD, Branch AD. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001;7:710-21.
56. Purcell R. The hepatitis C virus. Overview. Hepatology 1997;26(3 Suppl 1):11S-4S.
57. Ito T, Lai MM. An internal polypyrimidine tract binding protein binding site in the hepatitis C virus RNA attenuates translation, which is relieved by the 3′-untranslated sequence. Virology 1999;254:288-96.
58. Ito T, Lai MM. Determination of the secondary structure of and cellular protein binding to the 3′-untranslated region of the hepatitis C virus RNA genome. J Virol 1997;71:8698-706.
59. Wood J, Frederickson RM, Fields S, Patel AH. Hepatitis C virus 3′X region interacts with human ribosomal proteins. J Virol 2001;75:1348-58.
60. Spangberg K, Goobar-Larsson L, Wahren-Herlenius M, Schwartz S. The La protein from human liver cells interacts specifically with the U-rich region in the hepatitis C virus 3′ untranslated region. J Hum Virol 1999;2:296-307.
61. Santolini E, Migliaccio G, La MN. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 1994;68:3631-41.
62. Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, et al. Hepatitis C virus NS5A binds RNA-dependent RNA polymerase NS5B and modulates RdRP activity. J Biol Chem 2002;277(13):11149-55.
63. Hugle T, Fehrmann F, Bieck E, Kohara M, Krausslich HG, Rice CM, et al. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 2001;284:70-81.
64. Moradpour D, Kary P, Rice CM, Blum HE. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 1998;28:192-201.
65. Selby MJ, Choo QL, Berger K, Kuo G, Glazer E, Eckart M, et al. Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol 1993;74:1103-13.
66. Wengler G, Nowak T, Castle E. Description of a procedure which allows isolation of viral nonstructural proteins from BHK vertebrate cells infected with the West Nile flavivirus in a state which allows their direct chemical characterization. Virology 1990;177:795-801.
67. Cauchi MR, Henchal EA, Wright PJ. The sensitivity of cell-associated dengue virus proteins to trypsin and the detection of trypsin-resistant fragments of the nonstructural glycoprotein NS1. Virology 1991;180:659-67.
68. Tu H, Gao L, Shi ST, Taylor DR, Yang T, Mircheff AK, et al. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology 1999;263:30-41.
69. Shi ST, Polyak SJ, Hong T, Taylor DR, Gretch DR, Lai MMC. Hepatitis C Virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002;292:198-210.
70. Ide Y, Zhang LW, Chen M, Inchauspe G, Bahl C, Sasaguri Y, et al. Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A. Gene 1996;182:203-11.
71. Suzuki T, Matsuura Y, Harada T, Suzuki R, Saito I, Miyamura T. Molecular basis of subcellular localization of HCV core protein. Liver 1996;16:221-4.
72. Brass V, Bieck E, Montserret R, Wolk B, Hellings JA, Blum HE, et al. An amino-terminal amphipathic alfa-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 2002;277:8130-9.
73. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995;69:3980-6.
74. Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kimura K, et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun 1994;205:320-6.
75. Asabe SI, Tanji Y, Satoh S, Kaneko T, Kimura K, Shimotohno K. The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation. J Virol 1997;71:790-6.
76. Reed KE, Xu J, Rice CM. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J Virol 1997;71:7187-97.
77. Reed KE, Gorbalenya AE, Rice CM. The NS5A/NS5 proteins of viruses from three genera of the family Flaviviridae are phosphorylated by associated serine/threonine kinases. J Virol 1998;72:6199-206.
78. Hirota M, Satoh S, Asabe S, Kohara M, Tsukiyama K-K, Kato N, et al. Phosphorylation of nonstructural 5A protein of hepatitis C virus: HCV group-specific hyperphosphorylation. Virology 1999;257:130-7.
79. Koch JO, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol 1999;73:7138-46.
80. Neddermann P, Clementi A, De FR. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol 1999;73:9984-91.
81. Reed KE, Rice CM. Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. J Biol Chem 1999;274:28011-8.
82. Katze MG, Kwieciszewski B, Goodlett DR, Blakely CM, Neddermann P, Tan SL, et al. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Virology 2000;278:501-13.
83. Ide Y, Tanimoto A, Sasaguri Y, Padmanabhan R. Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alfa catalytic subunit. Gene 1997;201:151-8.
84. Kim J, Lee D, Choe J. Hepatitis C virus NS5A protein is phosphorylated by casein kinase II. Biochem Biophys Res Commun 1999;257:777-81.
85. Nousbaum JB, Polyak SJ, Sullivan DG, Larson AM, Carithers Jr RL, Gretch DR. Prospective Characterization of full-length HCV NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000;74:9028-38.
86. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-4.
87. Qin W, Yamashita T, Shirota Y, Lin Y, Wei W, Murakami S. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 2001;33:728-37.
88. Lohmann V, Komer F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001;75:1437-49.
89. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis c virus RNA replication by cell culture-adaptive mutations. J Virol 2001;75:4614-24.
90. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
91. Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, Liang TJ. Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 2001;121:1226-33.
92. Tan SL, Nakao H, He YP, Vijaysri S, Neddermann P, Jacobs BL, et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A 1999;96:5533-8.
93. He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL, et al. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol 2001; 75:5090-8.
94. Gale M, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999;73:6506-16.
95. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NSSA protein protects against TNF-alfa-mediated apoptotic cell death. Virus Res 2000;67:173-8.
96. Ezelle HJ, Balachandran S, Sicheri F, Polyak SJ, Barber GN. Analyzing the mechanisms of interferon-induced apoptosis using CrmA and hepatitis C virus NS5A. Virology 2001;281:124-37.
97. Park KJ, Choi SH, Lee SY, Hwang SB, Lai MM. Nonstructural 5A protein of hepatitis C virus modulates TNF-alfa-stimulated NF-kappa B activation. J Biol Chem 2002;277:13122-8.
98. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001;98:9599-604.
99. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 2001;276:12675-84.
100. Satoh S, Hirota M, Noguchi T, Hijikata M, Handa H, Shimotohno K. Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease(s) in mammalian cells. Virology 2000;270:476-87.
101. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527-31.
102. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-7.
103. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002;122:352-65.
104. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997;94(4):1200-5.
105. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16:185-94.
106. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-75.
107. Matsumoto M, Hsieh TY, Zhu NL, VanArsdale T, Hwang SB, Jeng KS, et al. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997;71:1301-9.
108. Zhu NL, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor I and enhances TNF-induced apoptosis. J Virol 1998;72:3691-7.
109. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996;226:176-82.
110. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R. Inhibition of tumor necrosis factor (TNF-alfa)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998;273:2256-9.
111. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas-and tumor necrosis factor alfa-mediated apoptosis via NF-kappa B activation. J Virol 1999;73:4713-20.
112. Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C Virus (HCV) core protein. Oncogene 2001;20:2606-10.
113. Fukuda K, Tsuchihara K, Hijikata M, Nishiguchi S, Kuroki T, Shimotohno K. Hepatitis C virus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli. Hepatology 2001;33:159-65.
114. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alfa. Hepatology 2000;32:958-61.
115. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999;258:100-7.
116. Lai MMC. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 2002;122:568-71.
117. Lai MMC, Ware CF. Hepatitis C virus core protein: possible roles in viral pathogenesis. Curr Top Microbiol Immunol 2000;242:117-34.
118. Goh PY, Tan YJ, Lim SP, Lim SG, Tan YH. The hepatitis C virus core protein interacts with NS5A and activates its caspase-mediated proteolytic cleavage. Virology 2001;290:224-36.
119. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
120. Khabar KSA, Dhalla M, Siddiqui Y, Zhou A. Effect of the deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in presence or absence of ribonuclease L: HSV-I replication is particularly sensitive to deficiency of the major IFN-mediated enzymes. J Interferon Cytokine Res 2000;20(7):653-9.
121. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J 1997; 16:6355-63.
122. Zhou A, Paranjape JM, Der SD, Williams BR, Silverman RH. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999;258:435-40.
123. Silverman RH. 2-5A dependent RNAse L: a regulated endoribonuclease in the interferon system. In: D'Alessio G, Riordan JF, editors. Ribonucleases: structure and function. New York: Academic Press; 1997. p. 515-51.
124. Silverman RH, Williams BR. Translational control perks up. Nature 1999;397:208-11.
125. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BRG, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990;62:379-90.
126. Meurs EF, Watanabe Y, Kadereit S, Barber GN, Katze MG, Chong K, et al. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. J Virol 1992;66:5804-14.
127. Pavlovic J, Zurcher T, Haller O, Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 1990;64:3370-5.
128. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999;73:8469-75.
129. Polyak SJ, Paschal D, McArdle S, Gale M, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999;29:1262-71.
130. Francois C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol 2000;74:5587-96.
131. Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999;117:1187-97.
132. Song J, Fujii M, Wang F, Itoh M, Hotta H. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J Gen Virol 1999;80:879-86.
133. Aizaki H, Saito S, Ogino T, Miyajima N, Harada T, Matsuura Y, et al. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins. J Interferon Cytokine Res 2000;20:1111-20.
134. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230:217-27.
135. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18:5208-18.
136. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A gene. J Clin Invest 1995;96:224-30.
137. Polyak SJ, Gerotto M. The molecular basis for responsiveness to anti-viral therapy in hepatitis C. Forum (Genova) 2000; 10:46-58.
138. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001;63:8-16.
139. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001;75:6095-106.
140. Girard S, Shalhoub P, Lescure P, Sabile A, Misek DE, Hanash S, et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 2002;295(2):272-83.
141. Khabar KS, Al-Zoghaibi F, Murayama T, Matsushima K, Mukaida N, Siddiqui Y, et al. Interleukin-8 selectively enhances cytopathic effect (CPE) induced by positive-strand RNA viruses in the human WISH cell line. Biochem Biophys Res Commun 1997;235:774-8.
142. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001;75:6209-11.
143. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000;72:391-8.
144. Neuman MG, Benhamou JP, Martinot M, Boyer N, Shear NH, Malkiewicz I, et al. Predictors of sustained response to alfa interferon therapy in chronic hepatitis C. Clin Biochem 1999;32:537-45.
145. Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001;34:173-82.
146. Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M, et al. Activation of the interferon-inducible 2′-5′-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 2000;74:8744-50.
147. Delhem N, Sabile A, Gajardo R, Podevin P, Abadie A, Blaton MA, et al. Activation of the interferon-inducible protein kinase PKR by Hepatocellular carcinoma derived-Hepatitis C virus core protein. Oncogene 2001;20:5836-45.
148. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-10.
149. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998;79:1373-81.